RecruitingPhase 2NCT07398664

H101 Plus TACE for r/m HNSCC

Recombinant Human Adenovirus 5 (H101) Combined With Transcatheter Arterial Chemoembolization (TACE) for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Single-Center, Prospective Study

Sponsor

West China Hospital

Enrollment

20 participants

Start Date

Mar 2, 2026

Study Type

INTERVENTIONAL

Conditions

Head and Neck Squamous Cell Carcinoma Oncolytic Virus TACE

Summary

This study evaluates H101 combined with transarterial chemoembolization (TACE) to enhance local tumor killing and immune activation while minimizing toxicity in r/m HNSCC patients.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called H101 and a procedure called TACE for people with head and neck squamous cell carcinoma, oncolytic virus, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGH101

H101 combined with transarterial chemoembolization (TACE) for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (r/m HNSCC)

PROCEDURETACE

H101 combined with transarterial chemoembolization (TACE) for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (r/m HNSCC)

Locations(1)

West China hospital

Chengdu, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07398664

Related Trials

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

NCT064375221 location

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors

NCT075892051 location

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

NCT047225237 locations

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NCT0646506938 locations

Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

NCT043753841 location